Last reviewed · How we verify
Closed loop with sensor and Insulin
A closed-loop insulin delivery system that uses continuous glucose monitoring to automatically adjust insulin infusion in real-time, mimicking the body's natural glucose regulation.
A closed-loop insulin delivery system that uses continuous glucose monitoring to automatically adjust insulin infusion in real-time, mimicking the body's natural glucose regulation. Used for Type 1 diabetes mellitus.
At a glance
| Generic name | Closed loop with sensor and Insulin |
|---|---|
| Also known as | Novolog |
| Sponsor | Albert Einstein College of Medicine |
| Drug class | Insulin delivery system / Artificial pancreas |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
The system combines a glucose sensor, insulin pump, and control algorithm to create an automated feedback loop that detects blood glucose levels and delivers appropriate insulin doses without manual user input. This artificial pancreas approach aims to maintain glucose homeostasis more effectively than conventional insulin therapy, reducing both hyperglycemic and hypoglycemic excursions in patients with type 1 diabetes.
Approved indications
- Type 1 diabetes mellitus
Common side effects
- Hypoglycemia
- Hyperglycemia
- Infusion set site reactions
- Sensor insertion site irritation
Key clinical trials
- Closed-loop in Adults With Type 2 Diabetes (NA)
- Two Way Crossover Closed Loop MPC vs Control IQ (NA)
- Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide (NA)
- Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes (NA)
- Real-World Evaluation of TouchCare Nano in Pediatric Type 1 Diabetes
- Closed-loop for People Living With Cystic Fibrosis Related Diabetes (NA)
- Closed-Loop Impact on Chronic Kidney Disease in Type 2 Diabetes (NA)
- Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: